Comparative Pharmacology
Head-to-head clinical analysis: PERPHENAZINE versus TARACTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERPHENAZINE versus TARACTAN.
PERPHENAZINE vs TARACTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Perphenazine is a typical antipsychotic that exerts its effects by blocking postsynaptic dopamine D2 receptors in the brain, particularly in the mesolimbic pathway. It also has antagonistic activity at alpha-adrenergic, histaminergic, and muscarinic receptors.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Oral: 4-16 mg 2-4 times daily; maximum 64 mg/day. Intramuscular: 5-10 mg every 6 hours; maximum 30 mg/day. Intravenous: 1-5 mg slow IV every 6 hours; maximum 10 mg/day.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
None Documented
None Documented
Clinical Note
moderatePerphenazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Perphenazine is combined with Fluticasone propionate."
Clinical Note
moderatePerphenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Perphenazine."
Clinical Note
moderatePerphenazine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Perphenazine."
Clinical Note
moderatePerphenazine + Methylphenidate
The terminal elimination half-life of perphenazine is approximately 8–12 hours in adults with normal hepatic function. This supports twice-daily dosing for maintenance therapy. In elderly patients or those with hepatic impairment, half-life may be prolonged.
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Perphenazine is extensively metabolized in the liver, primarily via CYP2D6, and eliminated predominantly as metabolites in urine (approximately 70%) and feces (about 30%). Less than 1% is excreted unchanged in urine.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic
"The risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate."